Translate Bio Inc (TBIO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Ronald C. Renaud Jr.
Employees:
200
29 HARTWELL AVENUE, LEXINGTON, MA 02421
617-945-7361

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction.

Data derived from most recent annual or quarterly report
Market Cap 2.824 Billion Shares Outstanding75.587 Million Avg 30-day Volume 1.896 Million
P/E Ratio54.4866 Dividend Yield0.0 EPS0.58
Price to Revenue9.7915 Debt to Equity0.0 EBITDA49.846 Million
Price to Book Value5.3411 Operating Margin17.2102 Enterprise Value1.532 Billion
Current Ratio8.796 EPS Growth1.333 Quick Ratio8.185
1 Yr BETA 1.5809 52-week High/Low 0.0 / Profit Margin17.9704
Operating Cash Flow Growth426.9841 Free Cash Flow to Firm (FCFF) TTM 277.055 Million Free Cash Flow to Equity (FCFE) TTM33.997 Million
Altman Z-Score3.351

Are you looking for these stocks instead?

View SEC Filings from TBIO instead.

View recent insider trading info

Translate Bio Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding TBIO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TBIO

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2021-09-14 by SUTHERLAND EVERETT RAND
  • 4: filed on 2021-09-14 by Smith Brendan
  • 4/A: filed on 2021-09-14 by RENAUD RONALD C JR
  • 4: filed on 2021-09-14 by BURGESS PAUL D.
  • 4: filed on 2021-09-14 by PLENGE ROBERT M
  • 4: filed on 2021-09-14 by MEYER ROBERT J.
  • 4: filed on 2021-09-14 by HUGHES OWEN
  • 4: filed on 2021-09-14 by DEMETRI GEORGE
  • 4: filed on 2021-09-14 by DEMETRI GEORGE
  • 4: filed on 2021-09-14 by BECKMAN DANIELLA

    • Events (8k)

  • 8-K: filed on 2021-09-14:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-03:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-06-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2021-04-20:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-03-23:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-02-25:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-12-28:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2020-12-22:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2020-08-25:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-07-20:
    Item 8.01: Other Events

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SANOFI

    • 10% Owner
    		 75,668,031 2021-09-14 0

    BECKMAN DANIELLA

    • Director
    		 0 2021-09-14 0

    HUGHES OWEN

    • Director
    		 0 2021-09-14 0

    DEMETRI GEORGE

    • Director
    		 0 2021-09-14 0

    MEYER ROBERT J.

    • Director
    		 0 2021-09-14 0

    BURGESS PAUL D. CHIEF OPERATING OFFICER, CLO

    • Officer
    • SECRETARY
    		 0 2021-09-14 0

    PLENGE ROBERT M

    • Director
    		 0 2021-09-14 0

    SUTHERLAND EVERETT RAND PRESIDENT

    • Officer
    		 0 2021-09-14 0

    SMITH BRENDAN CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2021-09-14 0

    FORMELA JEAN FRANCOIS

    • Director
    		 20,000 2021-06-16 0

    RENAUD RONALD C JR CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 2,025,152 2021-04-07 0

    BARBIER ANN CHIEF MEDICAL OFFICER

    • Officer
    		 70,000 2021-03-09 0

    WOOSTER RICHARD CHIEF SCIENTIFIC OFFICER

    • Officer
    		 70,000 2021-03-09 0

    LYNCH DANIEL

    • Director
    		 221,825 2020-12-31 0

    SHIRE HUMAN GENETIC THERAPIES, INC.

    TAKEDA PHARMACEUTICAL CO LTD

    • 10% Owner
    		 No longer subject to file 2020-06-30 0

    BAUPOST GROUP LLC/MA

    BAUPOST GROUP GP, L.L.C.

    KLARMAN SETH A

    • 10% Owner
    		 18,044,239 2020-06-26 0

    SCHROER JOHN R. CHIEF FINANCIAL OFFICER

    • Officer
    • TREASURER
    		 0 2020-03-03 0

    TAKEDA PHARMACEUTICAL CO LTD

    • 10% Owner
    		 7,078,945 2019-01-08 0

    GLAXOSMITHKLINE PLC

    • 10% Owner
    		 No longer subject to file 2018-07-02 0

    GALLAGHER BRIAN M. JR.

    • Director
    		 3,697,912 2018-07-02 0

    MRL VENTURES FUND LLC

    • 10% Owner
    		 No longer subject to file 2018-07-02 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    TRANSLATE BIO INC TBIO 2021-09-14 22:15:03 UTC -0.3776 0.4476 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 21:45:03 UTC -0.4139 0.4839 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 21:15:03 UTC -0.4139 0.4839 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 20:45:03 UTC -0.4139 0.4839 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 20:15:03 UTC -0.4139 0.4839 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 19:45:03 UTC -0.4139 0.4839 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 19:15:03 UTC -0.4139 0.4839 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 18:45:03 UTC -0.4139 0.4839 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 18:15:03 UTC -0.4139 0.4839 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 17:45:03 UTC -0.4139 0.4839 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 17:15:03 UTC -0.4139 0.4839 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 16:45:03 UTC -0.3776 0.4476 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 16:15:03 UTC -0.3776 0.4476 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 15:45:03 UTC -0.3776 0.4476 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 15:15:03 UTC -0.3776 0.4476 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 14:45:03 UTC -0.3776 0.4476 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 14:15:03 UTC -0.3776 0.4476 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 13:45:04 UTC -0.3776 0.4476 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 13:15:03 UTC -0.3776 0.4476 1200000
    TRANSLATE BIO INC TBIO 2021-09-14 12:45:03 UTC -0.3776 0.4476 1200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments